Active Filter(s):
Details:
This financing will enable MinervaX to progress its novel GBS vaccine GBS-NN/NN2, towards Phase III clinical trials in 2024. The Company is currently progressing two Phase II clinical trials in 470 pregnant persons across Denmark, United Kingdom, Uganda and South Africa.
Lead Product(s): GBS-NN,Aluminum
Therapeutic Area: Infections and Infectious Diseases Product Name: GBS-NN/NN2
Highest Development Status: Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: EQT Life Sciences
Deal Size: $56.8 million Upfront Cash: Undisclosed
Deal Type: Financing October 11, 2023